A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma

BACKGROUND: Patients with recurrent/metastatic uterine leiomyosarcoma (U-LMS) have a dismal prognosis. This phase II study aims to evaluate trabectedin efficacy and safety in advanced U-LMS. METHODS: Eligible patients had received ≥ one line of chemotherapy. Gemcitabine ± docetaxel naive patients we...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadducci, Angiolo, Grosso, Federica, Scambia, Giovanni, Raspagliesi, Francesco, Colombo, Nicoletta, Grignani, Giovanni, Casali, Paolo, Sanfilippo, Roberta, Buonadonna, Angela, Santoro, Armando, Bruzzone, Milena, Artioli, Grazia, Lorusso, Domenica, Biagioli, Elena, Fossati, Roldano, Galli, Francesca, Negri, Emanuele, Rulli, Eliana, Torri, Valter, D’Incalci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162262/
https://www.ncbi.nlm.nih.gov/pubmed/30057406
http://dx.doi.org/10.1038/s41416-018-0190-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162262/
https://www.ncbi.nlm.nih.gov/pubmed/30057406
http://dx.doi.org/10.1038/s41416-018-0190-y

Ejemplares similares